



Dr. Uwe Albrecht, MD, is the founder and CEO of Mediconomics GmbH with offices in the UK, Germany, and the US. He completed his education at the Faculty of Medicine of Marburg University. Dr. Albrecht has gained significant experience at senior levels in the medical industries through his positions with Behringwerke AG, the Glaxo Group Research in the UK, with Pharmakopius International in Germany, and with another medium-sized Pharmaceutical company. Dr Albrecht has contributed to over 20 original papers and communications in the world's scientific literature. His most recent contribution discusses the following topic: "Short Term Monotherapy in HIV Infected Patients with a Virus Entry Inhibitor Against the gp41 Fusion Peptide." Dr. Albrecht is a member of multiple professional organizations such as the Institute of Clinical Research

(MICR), the Faculty of Pharmaceutical Medicine (MFPM), Fellow of the Institute for Biomedical Science (FIBMS), the European Medical Writers Association, and the German Cancer Society to mention a few.